Depressive Disorder News and Research RSS Feed - Depressive Disorder News and Research

Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect -within 24 hours-and was well tolerated in patients with treatment-resistant major depressive disorder. [More]
Deutsche Forschungsgemeinschaft to establish 5 new Research Units

Deutsche Forschungsgemeinschaft to establish 5 new Research Units

Topics Range from Composite Structures to Personnel Decisions to Metastatic Cancer Progression / About Eleven Million Euros in Funding for Three Years [More]
NeuroSigma gets approval to market Monarch eTNS System in Australia

NeuroSigma gets approval to market Monarch eTNS System in Australia

NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that it has received approval from the Therapeutic Goods Administration to market its Monarch eTNS System in Australia. [More]
Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities. [More]
Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression. [More]
Seroxat in combination with acupuncture produces significant effect in patients with unipolar depression

Seroxat in combination with acupuncture produces significant effect in patients with unipolar depression

Acupuncture is more effective than oral antidepressants in improving depressive symptoms, and produces fewer side effects than tricyclic antidepressants. [More]

New report provides link between poor health and multiple forms of discrimination

Racial and sexual minorities, women, and obese people may face more health risks because of their disproportionate exposure to discrimination, according to a new report in the Journal of Health and Social Behavior. [More]
Adolescence is key developmental period for obesity and depression

Adolescence is key developmental period for obesity and depression

Depression and obesity have long been associated, but how they relate over time is less clear. New research from a Rutgers University-Camden professor shows that adolescent females who experience one of the disorders are at a greater risk for the other as they get older. [More]

Illness course impacts suicide risk in bipolar and depressive disorder

Differing illness course, rather than the illness itself, is the greatest determinant of the differential risk of suicide attempts between patients with bipolar disorder and those with major depressive disorder, study findings indicate. [More]
Researchers examine effect of vitamin D supplementation on depression

Researchers examine effect of vitamin D supplementation on depression

Vitamin D deficiency has been implicated in numerous health conditions in recent years, including depressed mood and major depressive disorder. [More]
Neuralstem announces results from Phase I trial using NSI-566 spinal cord stem cells in treatment of ALS

Neuralstem announces results from Phase I trial using NSI-566 spinal cord stem cells in treatment of ALS

Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology". [More]

Frontal lobe atrophy identified in poor sleepers

US researchers have used neuroimaging to show that war veterans with poor sleep quality have reduced frontal lobe volumes. [More]
Researchers discover two new gene regions connected to bipolar disorder

Researchers discover two new gene regions connected to bipolar disorder

First on top of the world and then in the depths of despair - this is what the extreme mood changes for people with bipolar disorder are like. Under the direction of scientists from Bonn, Mannheim and Basel, an international collaboration of researchers discovered two new gene regions that are connected to the prevalent disease. In addition, they were able to confirm three additional suspect genes. [More]

Alkermes initiates pivotal clinical development program for treatment of MDD

Alkermes plc today announced the initiation of the pivotal clinical development program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). [More]

Diagnostic errors common among patients with bipolar disorder

Russian study data bolster the existing body of evidence showing that bipolar disorder is often misdiagnosed as depression. [More]
Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease. [More]

Naurex's GLYX-13 receives FDA Fast Track designation

Naurex Inc. today announced that the U.S. Food and Drug Administration has granted Fast Track designation to the investigation of GLYX-13, the company's rapid-acting antidepressant in Phase 2 clinical development, as adjunctive therapy in major depressive disorder. [More]

Insomnia behaviours independently influence sleep in mood disorders

Behaviours associated with controlling sleep and managing the negative effects of insomnia are independently associated with disturbed sleep in patients with anxiety or depressive disorders, US research shows. [More]

BDNF abnormalities may predict bipolar disorder

Patients with bipolar disorder show abnormalities in the conversion of pro-brain derived neurotrophic factor to the mature form, which may be used to aid diagnosis of the condition. [More]
Urinary tract infections linked to acute psychosis relapse

Urinary tract infections linked to acute psychosis relapse

Patients with an acute episode of psychosis have a high incidence of urinary tract infections, report researchers. [More]